Table 2.
Procedural Characteristics
| Characteristic | Y2 (n = 673) | Y1 (n = 693) | p Value* | TR (n = 194) | TF (n = 1,172) | p Value* |
|---|---|---|---|---|---|---|
| Duration (min) | 76.7 (39.7) | 72.8 (44.6) | 0.1 | 75.8 (43.3) | 74.5 (42.1) | 0.7 |
| Lesions Treated (number) | 1.4 (0.7) | 1.4 (0.7) | 0.2 | 1.4 (0.7) | 1.4 (0.7) | >0.9 |
| Contrast Volume (mL) | 156 (68.3) | 150 (68.4) | 0.1 | 159 (66.8) | 151 (68.6) | 0.2 |
| Fluoroscopy (min) | 18.6 (12.9) | 17.2 (12.8) | 0.05 | 20.4 (12.9) | 17.5 (12.8) | 0.01 |
| Largest Sheath (Fr) | 6.3 (0.7) | 6.4 (0.8) | 0.1 | 6.0 (0.4) | 6.4 (0.8) | <0.001 |
| Treatment with Glycoprotein IIb/IIIa Inhibitors | ||||||
| Any IIb/IIIa Inhibitor | 16 (2%) | 107 (15%) | <0.001 | 1 (0.5%) | 122 (10%) | 0.002 |
| Abciximab | 13 (2%) | 38 (5%) | 0.001 | 1 (0.5%) | 50 (4%) | 0.03 |
| Eptifibatide | 3 (0.5%) | 69 (10%) | <0.001 | 0 (0%) | 72 (6%) | <0.001† |
| Treatment with Anticoagulants | ||||||
| Bivalirudin | 189 (28.1%) | 140 (20.2%) | <0.001 | 61 (31.4%) | 268 (22.9%) | 0.01 |
| Enoxaparin | 2 (0.3%) | 29 (4.2%) | <0.001 | 2 (1.0%) | 29 (2.5%) | 0.2 |
| Fondaparinux | 12 (1.8%) | 1 (0.1%) | 0.02 | 1 (0.5%) | 12 (1.0%) | 0.5 |
| Unfractionated Heparin | 588 (87.4%) | 616 (88.9%) | 0.4 | 175 (90.2%) | 1029 (87.8%) | 0.3 |
Data are presented as means (standard deviations) and n (%), which are raw values and do not account for multiple observations per individual patient. Abbreviations as in Table 1.
*
P-values take into consideration the fact that some observations were made on the same individuals.
†
For comparisons with a zero cell, Fisher’s exact tests were used.